JLK, Inc.

JLK, Inc.

KKRX:322510
3,740.00
KRW
-40.00
(-1.06%)
-596.13EPS
120.24BMarket Cap
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
12.9
53.76
14.38
234.56
195.98
175.92
122.36
66.1
132.54
107.34
Basic EPS, GAAP
-1,290.5
-929.9
-666.73
-398.97
-392.06
-464.18
-360.02
-623
-540
-596.13
Free Cash Flow per Basic Share
-675.84
-673.24
-425.93
-833.98
-384.6
-431.2
-331.52
-509.19
-503.12
-511.32
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-457.28
322.45
1,908.73
1,593.96
1,246.12
850.01
568.18
1,957.72
1,641.99
1,357.91
Tangible Book Value per Share
-502.22
267.74
1,865.3
1,563.3
1,205.61
829.88
553.88
1,946.57
1,635.3
1,353.42
Basic Weighted Avg Shares
7
7
16
19
19
19
20
22
25
25
Sales/Revenue/Turnover
84
363
230
4,490
3,786
3,415
2,489
1,428
3,339
2,724
Operating Margin (%)
-2,465.69
-1,272.23
-4,702.46
-167.8
-196.1
-252.62
-287.17
-891.88
-395.33
-501.82
Depreciation Expense
519
287
760
859
1,017
1,091
917
731
768
765
Net Income, GAAP
-8,411
-6,277
-10,644
-7,637
-7,574
-9,012
-7,323
-13,454
-13,606
-15,126
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-10,002.02
-1,729.7
-4,637.28
-170.09
-200.05
-263.86
-294.23
-942.46
-407.43
-555.37
Working Capital
2,365
6,174
35,902
16,660
9,727
7,246
365
39,804
25,609
20,522
LT Debt
1,472
1,145
64
11,668
11,508
16,275
13,056
15,043
8,056
9,181
Total Equity
-8,644
6,095
36,301
30,669
24,260
16,599
11,725
49,316
41,363
34,705
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
-50.21
-22.81
-27.67
-44.28
-51.67
-44.08
-30.01
-38.5

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
22,036
22,129
22,142
LT Borrowings
8,037
8,571
9,099
LT Finance Leases
19
101
82
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
25
26
26
Market Capitalization
140,049
173,779
120,240

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
49,725
47,521
44,802
Cash, Cash Equivalents & STI
46,798
43,874
41,783
Accounts Receivable, Net
1,226
1,189
1,271
Inventories
19
16
16
Total Current Liabilities
24,116
24,094
24,280
Payables & Accruals
- -
- -
- -
ST Debt
22,036
22,129
22,142
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
44.53%
-16.13%
Free Cash Flow
- -
3.62%
15.29%
Net Income, GAAP
- -
16.85%
1.13%
Sales/Revenue/Turnover
- -
7.74%
133.94%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
136
228
250
813
1,428
2025
485
1,063
895
897
3,339
2026
412
520
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-144.24
-121.99
-140.83
-110.89
-623
2025
-128
-112
-85.99
-214.49
-540
2026
-149.69
-146
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Dong-Min Kim
Full Time Employees
72
Sector
Technology services
Industry
Packaged software
Address
#204, 10, Yangcheongsongdae-gil Cheongju-si NC South Korea
IPO Date
Dec 11, 2019
Business
JLK, Inc. JLK, Inc. (322510.KQ) develops and provides AI-driven medical diagnosis solutions, focusing on brain disorders, cancer detection, and healthcare data management; its core offerings include the MEDIHUB STROKE total solution for ischemic stroke, hemorrhagic stroke, brain aneurysm analysis via CT, CTP, MRI, MRA imaging; dementia and brain aging tools like ATROSCAN; cancer solutions such as JBS-01K for stroke, JPC-01K for prostate cancer, JVIEWER-X for chest X-ray, JLD-01K for chest CT, JBD-01K for breast cancer, JDP-01A for prostate pathology, and digital pathology platforms; additional services encompass MEDIHUB TELE for AI-integrated telemedicine, Hello Data platforms for medical, autonomous driving, and industrial data management, and AI security solutions. The company operates primarily in South Korea with global expansions through subsidiaries in Japan (JLK Inspection Japan) and the US (JLK Inspection USA), holding over 60 regulatory certifications including MFDS Korea, PMDA Japan, Europe CE, Thai FDA, and recently FDA clearance for its subdural hemorrhage detection tool, alongside approvals in Indonesia, Turkey, New Zealand, Vietnam, and Malaysia; it targets hospitals, physicians, and telemedicine users worldwide via partnerships with over 23 university hospitals and entities like Japan's DoctorNet for lung solutions and Clinton Health Access Initiative for TB screening. Founded in 2014 and headquartered at JLK Tower in Seoul, South Korea, with prior facilities in Cheongju, JLK, Inc. lists on KOSDAQ since December 2019 as the first AI medical firm to do so; recent developments feature establishment of subsidiary JLK BIO in 2021 for AI drug discovery via DeepHits platform, FDA clearance for SDH detection in 2025 bringing total US approvals to seven with eight more submissions planned, innovative medical device designations for JBS-01K, national R&D project wins for AI cancer pathology, and regulatory sandbox approval for overseas telemedicine.